Skip to main content
Caplight Logo









Homexin

Homexin

Private
TaipeiHealthcare & Life Scienceshttps://homexin.com.tw

Last Round

Accelerator

Aug 2, 2022

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Homexin operates in Healthcare & Life Sciences and is based in Taipei. Its latest recorded funding round was an Accelerator round in August 2022.

Homexin is a healthcare technology company that provides a digital platform for matching patients and families with qualified caregivers for hospital and in-home care.

Sector

Healthcare & Life Sciences

Verticals

Home & Lifestyle, Patient Engagement

Business Model

B2C

Customer Profile

Marketplace Commission

AI Layer

Application

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Homexin Comparables

Compare Homexin with similar companies based on industry and business-model similarity.

Homexin comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
GHS Advanced Inc.
91%
Care724
88%
Ucarer
86%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Homexin Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorAug 2, 2022
SeedFeb 1, 2022
AcceleratorAug 12, 2021
AcceleratorJan 1, 2021
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Homexin Investors

Notable investors and investment history

Homexin investors
InvestorRounds
AppWorksAccelerator
Taipei Medical University Biomedical AcceleratorAccelerator
500 GlobalSeed
BE Health VenturesAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 111% MoM, reaching 25.9K.

  • Jul 27, 2026

    Monthly visitors grew 136% MoM, reaching 12.3K.

Book a demo to see all signals

For institutional investors. Book with your work email.

Homexin Filings

Explore SEC and related filing metadata, where available.

Homexin filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Homexin's valuation, stock price, and market status.

Is Homexin a public or private company?

Homexin is a private company.

What is the current stock price of Homexin?

Homexin is a private company, so its shares have no public market price. Caplight tracks Homexin's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Homexin worth (valuation)?

Valuation information for Homexin is not publicly available.

Can I buy Homexin stock?

Homexin shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Homexin's last funding round?

Homexin's most recent funding round was Accelerator on August 2, 2022.

Who are the main investors in Homexin?

Key investors in Homexin include 500 Global.

Will Homexin IPO soon?

No public IPO plans have been announced for Homexin.

How can I track Homexin secondary market activity?

Caplight tracks bids, offers, and trades in Homexin's shares on secondary markets.

Firmographic Details

HeadquartersTaipei
Employee Range1
Year Founded2019
Last FundingAug 2, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?